Canadian Journal of General Internal Medicine
26 Volume 13, Special Issue 1, 2018
6. Parkash R, Maisel WH, Toca FM, Stevenson WG. Atrial fibrillation in heart
failure: high mortality risk even if ventricular function is preserved. AmHeart
Kirchhof P, Schmalowsky J, Pittrow D et al. Management of patients with
atrial fibrillation by primary-care physicians in Germany: 1-year results of
the ATRIUM registry. Clin Cardiol 2014;37:277–84.
Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB. Impact of
atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med
McDonald AJ, Pelletier AJ, Ellinor PT, Camargo CA, Jr. Increasing US
emergency department visit rates and subsequent hospital admissions for
atrial fibrillation from 1993 to 2004. AnnEmergMed 2008;51:58–65.
Khaykin Y, Morillo CA, Skanes AC, McCracken A, Humphries K, Kerr
CR. Cost comparison of catheter ablation and medical therapy in atrial
fibrillation. Journal of cardiovascular electrophysiology 2007;18:907–13.
Gladstone DJ, Bui E, Fang J et al. Potentially preventable strokes in high-risk
patients with atrial fibrillation who are not adequately anticoagulated. Stroke
Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of
oral anticoagulants in atrial fibrillation: a systematic review. Am J Med
Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219–226.
Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial
fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med
Dixit S, Marchlinski FE, Lin D et al. Randomized ablation strategies for
the treatment of persistent atrial fibrillation: RASTA study. Circ Arrhythm
Saygili E, Rana OR, Saygili E et al. Losartan prevents stretch-induced
electrical remodeling in cultured atrial neonatal myocytes. Am J Physiol
Heart Circ Physiol 2007;292:H2898-H2905.
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation
begets atrial fibrillation. A study in awake chronically instrumented goats.
Scherlag BJ, Patterson E, Po SS. The neural basis of atrial fibrillation. J
19. Kistler PM, Sanders P, Dodic M et al. Atrial electrical and structural
abnormalities in an ovine model of chronic blood pressure elevation after
prenatal corticosteroid exposure: implications for development of atrial
fibrillation. Eur Heart J 2006;27:3045–3056.
20. Anter E, Di Biase L, Contreras-Valdes FM et al. Atrial Substrate and Triggers
of Paroxysmal Atrial Fibrillation in Patients With Obstructive Sleep Apnea.
Circ Arrhythm Electrophysiol 2017;10.
Gillis AM, Verma A, Talajic M, Nattel S, Dorian P. Canadian cardiovascular
society atrial fibrillation guidelines 2010: rate and rhythm management.
Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian
cardiovascular society atrial fibrillation guidelines 2010: prevention of stroke
and systemic thromboembolism in atrial fibrillation and flutter. CanJCardiol
23. Healey JS, Parkash R, Pollak PT, Tsang TS, Dorian P. Canadian
Cardiovascular Society 2010 Atrial Fibrillation Guidelines: Chapter 2 - Atrial
Fibrillation: Etiology and Initial Investigations. CanJCardiol 2011.
Wyse DG, Van Gelder IC, Ellinor PT et al. Lone atrial fibrillation: does it
exist? J Am Coll Cardiol 2014;63:1715–23.
25. Schnabel RB, Yin X, Gona P et al. 50 year trends in atrial fibrillation
prevalence, incidence, risk factors, and mortality in the Framingham Heart
Study: a cohort study. Lancet 2015;386:154–62.
26. Staerk L, Wang B, Preis SR et al. Lifetime risk of atrial fibrillation according
to optimal, borderline, or elevated levels of risk factors: cohort study based on
longitudinal data from the Framingham Heart Study. BMJ 2018;361:k1453.
27. Van Wagoner DR, Piccini JP, Albert CM et al. Progress toward the prevention
and treatment of atrial fibrillation: A summary of the Heart Rhythm Society
Research Forum on the Treatment and Prevention of Atrial Fibrillation,
Washington, DC, December 9-10, 2013. Heart Rhythm 2015;12:e5-e29.
Belardinelli R, Georgiou D, Ginzton L, Cianci G, Purcaro A. Effects of
moderate exercise training on thallium uptake and contractile response to
low-dose dobutamine of dysfunctional myocardium in patients with ischemic
cardiomyopathy. Circulation 1998;97:553–561.
29. Osbak PS, Mourier M, Kjaer A, Henriksen JH, Kofoed KF, Jensen GB. A
randomized study of the effects of exercise training on patients with atrial
fibrillation. AmHeart J 2011;162:1080–1087.
Reed JL, Mark AE, Reid RD, Pipe AL. The effects of chronic exercise
training in individuals with permanent atrial fibrillation: a systematic review.
Giacomantonio NB, Bredin SS, Foulds HJ, Warburton DE. A systematic
review of the health benefits of exercise rehabilitation in persons living with
atrial fibrillation. CanJCardiol 2013;29:483–491.
Qureshi WT, Alirhayim Z, Blaha MJ et al. Cardiorespiratory Fitness and Risk
of Incident Atrial Fibrillation: Results From the Henry Ford Exercise Testing
(FIT) Project. Circulation 2015;131:1827–34.
Pathak RK, Elliott A, Middeldorp ME et al. Impact of CARDIOrespiratory
FITness on Arrhythmia Recurrence in Obese Individuals With Atrial
Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol 2015;66:985–96.
Abed HS, Wittert GA, Leong DP et al. Effect of weight reduction and
cardiometabolic risk factor management on symptom burden and severity
in patients with atrial fibrillation: a randomized clinical trial. JAMA
35. Rienstra M, Hobbelt AH, Alings M et al. Targeted therapy of underlying
conditions improves sinus rhythm maintenance in patients with persistent
atrial fibrillation: results of the RACE 3 trial. Eur Heart J 2018.
Pathak RK, Middeldorp ME, Meredith M et al. Long-Term Effect of Goal
Directed Weight Management in an Atrial Fibrillation Cohort: A Long-term
Follow-Up StudY (LEGACY Study). J Am Coll Cardiol 2015.
Parkash R, Verma A, Tang AS. Persistent atrial fibrillation: current approach
and controversies. Curr Opin Cardiol 2010;25:1–7.
38. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent,
risk factor for complications, and potential therapeutic target. Am J Cardiol
Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis,
and predisposing conditions for atrial fibrillation: population-based
estimates. Am J Cardiol 1998;82:2N-9N.
Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM.
Influence of systolic and diastolic blood pressure on the risk of incident atrial
fibrillation in women. Circulation 2009;119:2146–2152.
Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces
new-onset atrial fibrillation and subsequent stroke compared to atenolol:
the Losartan Intervention For End Point Reduction in Hypertension (LIFE)
study. J Am Coll Cardiol 2005;45:712–719.
42. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with
angiotensin-converting enzyme inhibitors and angiotensin receptor blockers:
a meta-analysis. J Am Coll Cardiol 2005;45:1832–1839.
43. Disertori M, Latini R, Barlera S et al. Valsartan for prevention of recurrent
atrial fibrillation. N Engl J Med 2009;360:1606–1617.
Yusuf S, Healey JS, Pogue J et al. Irbesartan in patients with atrial fibrillation.
N Engl J Med 2011;364:928–38.
45. Parkash R, Wells GA, Sapp JL et al. Effect of Aggressive Blood Pressure
Control on the Recurrence of Atrial Fibrillation After Catheter Ablation:
A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate
Modification With Aggressive Blood Pressure Control]). Circulation
46. Leung AA, Daskalopoulou SS, Dasgupta K et al. Hypertension Canada’s 2017
Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of
Hypertension in Adults. Can J Cardiol 2017;33:557–576.
47. Marini C, De SF, Sacco S et al. Contribution of atrial fibrillation to incidence
and outcome of ischemic stroke: results from a population-based study.
48. Holmqvist F, Guan N, Zhu Z et al. Impact of obstructive sleep apnea and
continuous positive airway pressure therapy on outcomes in patients with
atrial fibrillation-Results from the Outcomes Registry for Better Informed
Does Lifestyle Impact Risk, Burden, and Symptomatology of Atrial Fibrillation?